Cognito Therapeutics, which is in late-stage development of its device to treat neurodegenerative diseases like Alzheimer’s, hauled in ...

Expecting pivotal data this year, the company has raised a Series C round to support the launch of a noninvasive device ...

Thomas Fagan, Executive Vice President, Alzheimer’s Portfolio, Cognito Therapeutics. Mr. Fagan brings more than 25 years of leadership experience across the pharmaceutical, medi ...

The Massachusetts-based company will use the funds to advance its Spectris neurotechnology platform that uses visual and auditory stimulation to treat Alzheimer’s disease.

Cognito Therapeutics today announced that it completed the final close of its oversubscribed Series C financing round.

With a pivotal trial readout for Cognito’s Spectris due later this year, the company anticipates launching the Alzheimer’s ...

Cognito's $105 million Series C will advance their pivotal FDA study, expand clinical neurology partnerships, and expand work past Alzheimer's into Parkinsons and beyond.

Cognito raised $105 million as it awaits trial data that it hopes will convince the FDA to authorize its Alzheimer’s treatment device.

Series C proceeds position Spectris for pivotal top-line data, regulatory submission, and launch planning ahead of a targeted ...

Cognito Therapeutics has spent the better part of the last decade developing neuromodulation technology that it claims could stop and even reverse the progression of Alzheimer’s and other ...